F2 and COVID-19: During COVID-19, ~60% of patients with severe disease develop COVID-19-associated coagulopathy (CAC), which is characterized by elevated levels of D-dimer in the circulation, unchanged or decreased platelet count, shortened prothrombin time, and increased risk of thrombosis (46).